Document:

Termination Agreement dated August 19, 2005

 Exhibit 10.52 
  
 TERMINATION AGREEMENT 
  
 THIS TERMINATION AGREEMENT (the “Termination Agreement”) is made and entered
into as of August 19, 2005 by and between SALIX PHARMACEUTICALS, INC., a California corporation (“Salix”), and ALTANA PHARMA US, INC.,
a Delaware corporation (“Altana”). Salix and Altana may be referred to herein individually as a “Party” or collectively as “Parties.” 
  
 BACKGROUND 
  
 The Parties previously entered into a Co-Promotion Agreement dated March 2, 2005 (the “Co-Promotion Agreement”) to collaborate with each other
to optimize the sales of rifaximin, an antibiotic owned by Salix and marketed and sold under the name “XifaxanTM.” 
  
 The Parties now desire to terminate the Co-Promotion Agreement in accordance with the terms of this Termination Agreement. 
  
 NOW, THEREFORE, in consideration of the mutual
covenants contained in this Termination Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, agree as follows: 
  
 1. TERMINATION OF THE
CO-PROMOTION AGREEMENT 
  
 Notwithstanding the 90-day notice period in Section 7.1 of the Co-Promotion Agreement, the Parties agree that the Co-Promotion Agreement is terminated effective as of September 6, 2005 (the “Termination
Date”). 
  
 2. CONSEQUENCES OF
TERMINATION 
  
 The Parties agree that,
notwithstanding Section 12.14 of the Co-Promotion Agreement, Sections 3.1(d), 5.3 and 5.4 of the Co-Promotion Agreement are terminated as of the Termination Date and shall not survive the termination of the Co-Promotion Agreement pursuant to this
Termination Agreement. 
  
 The Parties agree that the only payment
due to Altana from Salix under Section 5.2 of the Agreement shall be one and one half of a quarterly minimum payment under Section 5.2(b) of the Co-Promotion Agreement. The Parties further agree that no payments are due to either party under the
Co-Promotion Agreement for any activity after the Termination Date. 
  
 On or prior to the Termination Date, Altana shall provide Salix with a list of the healthcare professionals (name and contact information) who have written at least one prescription for Xifaxan as a result of Altana’s efforts under the
Co-Promotion Agreement. Salix shall use this list solely to contact such healthcare professionals and make arrangements to continue to provide them with rifaximin product information and samples.  

 3. MISCELLANEOUS 
  
 3.1 Complete Understanding; Modification. This Termination Agreement constitutes the complete and exclusive
understanding and agreement of the Parties and supersedes all prior understandings and agreements, whether written or oral, with respect to the subject matter hereof. Any waiver, modification or amendment of any provision of this Termination
Agreement will be effective only if in writing and signed by the Parties. 
  
 3.2 Counterparts. This Termination Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

  
 3.3 Governing Law. This Termination Agreement and the
rights and obligations of the Parties hereunder shall be construed in accordance with and be governed by the laws of the State of Delaware (without giving effect to the principles thereof relating to conflicts of law). Any legal action or proceeding
pursuant to this Termination Agreement may be brought in the state courts of the State of Delaware or the federal courts located in, or having jurisdiction with respect to the State of Delaware, and, by execution and delivery of this Agreement, each
of the Parties hereby accepts for itself and in respect of its property, generally and unconditionally, the non-exclusive jurisdiction of the aforesaid courts. 
  

3.4 Press Release. The Parties hereby agree to release the joint press release regarding this Termination Agreement in substantially the form
attached hereto as Exhibit A. 
  
 [Signature Page to Follow]

  

 2 

 IN WITNESS WHEREOF, the Parties hereto have duly
executed this Termination Agreement as of the Termination Date. 
  

							
	SALIX PHARMACEUTICALS, INC.	  	ALTANA PHARMA US, INC.
				
	By:	  	 /s/ Carolyn J. Logan

	  	By:	  	 /s/ Deborah Tanner

	Name:	  	Carolyn J. Logan	  	Name:	  	Deborah Tanner
	Title:	  	President and CEO	  	Title:	  	Vice President and General Counsel

  
 Signature Page
for Termination Agreement 
  

 3Notice of Issuance of Restricted Stock for Nickolas W. Vande Steeg

 Exhibit 10.1 
  

			
	Name:	 	NICKOLAS W. VANDE STEEG
		
	 PID:
	 	 xxxxxxxxx

	
	August 17, 2005

  
 NOTICE OF ISSUANCE
OF RESTRICTED STOCK 
  
 On August 11, 2004, pursuant to the 2003 Stock
Incentive Plan (the “Plan”), the Management Development and Compensation Committee of the Board of Directors (the “Committee”) of Parker-Hannifin Corporation (the “Corporation”) granted to the Chief Executive Officer
the authority on behalf of the Corporation to issue to you restricted shares of Parker-Hannifin Corporation Common Stock (“Shares”). Based on such authority, I hereby confirm that 5,000 Shares will be issued to you subject to the following
terms and conditions: 
  

	1.	Shares will be issued as of August 17, 2005. 

  

	2.	Ownership of the Shares will become vested (i.e., unrestricted) on August 17, 2008. During the vesting period, the Shares cannot be sold or otherwise transferred or assigned.

  

	 	a.	Shares vest immediately in the event of your retirement at or after December 31, 2006. 

  

	 	b.	Shares are forfeited in the event of (i) your death or disability; (ii) your involuntary termination of employment (except due to retirement as specified in (a) above); or (iii) the
involuntary termination of your employment. 

  

	3.	Shares will vest immediately in the event of a “change in control” of the Corporation (as defined in the Plan). 

  

	4.	Certificates representing the Shares will not be issued during the vesting period. Rather, the Shares will be issued in an uncertificated book entry format at the transfer agent.

  

	5.	Shares will earn non-refundable dividends during the vesting period, payable directly to you. 

  

	6.	Upon vesting, the value of the Shares will become taxable income to you. You will be obligated to immediately reimburse the Corporation for all withholding taxes payable by the
Corporation at such time. At your election, you may surrender a portion of the Shares to satisfy such withholding taxes. 

	7.	To the extent not otherwise specified above, the issuance of the Shares is subject to the terms and conditions of the Plan. 

  
 Please confirm your receipt of this Notice and indicate your acknowledgment and agreement to
the terms specified herein by signing and returning a copy of this Notice to Tom Piraino. 
  
 Sincerely yours, 
  
 /s/ D. E. Washkewicz

  
 Donald E. Washkewicz 
 Chairman and Chief Executive Officer 
  

					
	ACKNOWLEDGED AND AGREED:	 	 	 	 
			
	 /s/ N.W. Vande Steeg

	 	 	 	Date: 8/17/2005
	Nickolas W. Vande SteegForm of Non-statutory Stock Option Agreement for Executive Officers

 Exhibit 10.1 
  
 Nonstatutory Stock Option Agreement for Executive Officers 
 Granted Under 2005 Stock Incentive Plan 
  
 1. Grant of Option. 
  
 The following terms and conditions apply to the grant by Boston Communications Group, Inc., a Massachusetts corporation (the “Company”), on the date set forth on the cover sheet (the “Grant Date”), to Participant, of an
option to purchase, in whole or in part, on the terms provided herein and in the Company’s 2005 Stock Incentive Plan (the “Plan”), that number of shares of common stock, $.01 par value per share, of the Company (“Common
Stock”) (the “Shares”) at the price per Share indicated thereon. Unless earlier terminated, this option shall expire on the tenth anniversary of the Grant Date (the “Final Exercise Date”). 
  
 It is intended that the option evidenced by this agreement shall not be an
incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context, the term “Participant”, as
used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms. 
  
 2. Vesting Schedule. 
  
 This option will become exercisable (“vest”) in installments as outlined on the cover sheet. This option shall expire upon, and will not be exercisable after, the Final Exercise Date. The vesting schedule is
also subject to the provisions of [INSERT LEGAL CITE - CHANGE IN CONTROL AGREEMENT]. 
  
 The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all
shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan. 
  
 3. Exercise of Option. 
  
 (1) Form of Exercise. Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company at its
principal office, accompanied by this agreement, and payment in full in the manner herein provided. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any
fractional share or for fewer than ten whole shares. 
  
 (2)
Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the
Grant Date, an employee, officer or director of, or consultant or advisor to, the Company or any parent or subsidiary of the Company as defined in Section 424(e) or (f) of the Code (an “Eligible Participant”). 
  
 (3) Termination of Relationship with the Company. If the Participant
ceases to be an Eligible Participant for any reason the right to exercise this option shall terminate 90 days after such cessation (but in no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent
that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any
employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon written notice to the Participant from the Company
describing such violation. 

 (4) Exercise Period Upon Death or Disability. If the Participant dies or becomes disabled (within
the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant this option shall be exercisable, within the period of one year following the date of death or disability of the Participant by
the Participant, provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable
after the Final Exercise Date. 
  
 4. Withholding.  
  
 No Shares will be issued pursuant to the exercise of this option unless and
until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option. 
  
 5. Nontransferability of Option. 
  
 This option may not be sold, assigned, transferred, pledged or otherwise
encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 
  
 6. Provisions of the Plan. 
  
 This option is subject to the provisions of the Plan, a copy of which is
furnished to the Participant with this option.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]